Pralsetinib in patients with RET fusion-positive non-small-cell lung cancer: A plain language summary of the ARROW study

  1. Griesinger, F.
  2. Curigliano, G.
  3. Subbiah, V.
  4. Baik, C.S.
  5. Tan, D.S.
  6. Lee, D.H.
  7. Misch, D.
  8. Garralda, E.
  9. Kim, D.-W.
  10. van der Wekken, A.J.
  11. Gainor, J.F.
  12. Paz-Ares, L.
  13. Liu, S.V.
  14. Kalemkerian, G.P.
  15. Bowles, D.W.
  16. Mansfield, A.S.
  17. Lin, J.J.
  18. Smoljanovic, V.
  19. Rahman, A.
  20. Zalutskaya, A.
  21. Louie-Gao, M.
  22. Boral, A.L.
  23. Mazières, J.
Aldizkaria:
Future oncology (London, England)

ISSN: 1744-8301

Argitalpen urtea: 2024

Alea: 20

Zenbakia: 6

Orrialdeak: 297-306

Mota: Berrikuspena

DOI: 10.2217/FON-2023-0155 GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus